Estrogen signaling in livers of male mice with hepatocellular carcinoma induced by exposure to arsenic in utero

Journal of the National Cancer Institute

Volumn 96, Issue 6, 2004, Pages 466-474

  Waalkes, Michael P ^a   Liu, Jie ^a   Chen, Hua ^a   Xie, Yaxiong ^a   Achanzar, William E ^a   Zhou, Yun Su ^b   Cheng, Min Liang ^c   Diwan, Bhalchandra A ^d  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b Southwest Prefecture Endemic Prevention Station   (China)

^c GUIZHOU MEDICAL UNIVERSITY   (China)

^d SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; CYCLIN D1; CYTOCHROME P450; CYTOCHROME P450 2A; CYTOCHROME P450 2A4; CYTOCHROME P450 2B9; CYTOCHROME P450 7B1; DNA; ESTROGEN; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; UNCLASSIFIED DRUG; CARCINOGEN; CYP2A4 PROTEIN, MOUSE; CYP2B9 PROTEIN, MOUSE; CYP7B1 PROTEIN, HUMAN; ESTROGEN RECEPTOR; ORGANOARSENIC DERIVATIVE; OXYSTEROL 7 ALPHA HYDROXYLASE; OXYSTEROL 7-ALPHA-HYDROXYLASE; STEROID MONOOXYGENASE; UNSPECIFIC MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA METHYLATION; FEMALE; FEMINIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; ONCOGENE; POLYMERASE CHAIN REACTION; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; ANIMAL; CHEMICALLY INDUCED DISORDER; ENVIRONMENTAL EXPOSURE; ENZYMOLOGY; FETUS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER DISEASE; LIVER TUMOR; METABOLISM;

ANIMALS; ARSENICALS; ARYL HYDROCARBON HYDROXYLASES; CARCINOGENS; CYCLIN D1; CYTOCHROME P-450 ENZYME SYSTEM; DNA METHYLATION; ENVIRONMENTAL EXPOSURE; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FETUS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER DISEASES; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STEROID HYDROXYLASES;

EID: 1642350435     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh070     Document Type: Article

References (61)

1. IARC. Arsenic and arsenic compounds. In: IARC monograph on the evaluation of the carcinogenic risk to humans-overall evaluations of carcinogenicity: An update of IARC monographs 1 to 42. Suppl. 7. Lyon (France): IARC; 1987. p. 100-6.
2. National Research Council. Arsenic in the drinking water. Washington (DC): National Academy Press; 1999. p. 1-310.
3. Bates MN, Smith AH, Hopenhayn-Rich C. Arsenic ingestion and internal cancers: A review. Am J Epidemiol 1992;135:462-76.
4. Smith AH, Hopenhayn-Rich C, Bates MN, Goeden HM, Hertz-Picciotto I, Duggan HM, et al. Cancer risks from arsenic in drinking water. Environ Health Perspect 1992;97:259-67.
5. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12: S294-308.
6. Lewis DR, Southwick JW, Ouellet-Hellstrom R, Rench J, Calderon RL. Drinking water arsenic in Utah: A cohort mortality study. Environ Health Perspect 1999;107:359-65.
7. Morales KH, Ryan L, Kuo TL, Wu MM, Chen CJ. Risk of internal cancers from arsenic in drinking water. Environ Health Perspect 2000;108:655-61.
8. Anderson LM, Diwan BA, Fear NT, Roman E. Critical windows of exposure for children's health: Cancer in human epidemiological studies and neoplasms in experimental animal models. Environ Health Perspect 2000;108 Suppl 3:573-94.
9. Waalkes MP, Diwan BA, Ward JM, Devor DE, Goyer RA. Renal tubular tumors and atypical hyperplasias in B6C3F1 mice exposed to lead acetate during gestation and lactation occur with minimal chronic nephropathy. Cancer Res 1995;55:5265-71.
10. Diwan BA, Anderson LM, Ward JM, Henneman JR, Rice JM. Transplacental carcinogenesis by cisplatin in F344/NCr rats: Promotion of kidney tumors by postnatal administration of sodium barbital. Toxicol Appl Pharmacol 1995;132:115-21.
11. Diwan BA, Kasprzak KS, Rice JM. Transplacental carcinogenic effects of nickel(II) acetate in the renal cortex, renal pelvis and adenohypophysis in F344/NCr rats. Carcinogenesis 1992;13:1351-7.
12. Lindgren A, Danielsson BR, Dencker L, Vahter M. Embryotoxicity of arsenite and arsenate: Distribution in pregnant mice and monkeys and effects on embryonic cells in vitro. Acta Pharmacol Toxicol (Copenh) 1984;54:311-20.
13. Chattopadhyay S, Bhaumik S, Nag Chaudhury A, Das Gupta S. Arsenic induced changes in growth development and apoptosis in neonatal and adult brain cells in vivo and in tissue culture. Toxicol Lett 2002;128:73-84.
14. Concha G, Vogler G, Lezcano D, Nermell B, Vahter M. Exposure to inorganic arsenic metabolites during early human development. Toxicol Sci 1998;44:185-90.
15. Waalkes MP, Ward JM, Liu J, Diwan BA. Transplacental carcinogenicity of inorganic arsenic in the drinking water: Induction of hepatic, ovarian, pulmonary, and adrenal tumors in mice. Toxicol Appl Pharmacol 2003; 186:7-17.
16. Zhou YS, Du H, Cheng ML, Liu J, Zhang XJ, Xu L. The investigation of death from diseases caused by coal-burning type of arsenic poisoning. Zhong Guo Di Fang Bing Zue Za Zhi 2002;21:484-6.
17. Centeno JA, Mullick FG, Martinez L, Page NP, Gibb H, Longfellow D, et al. Pathology related to chronic arsenic exposure. Environ Health Perspect 2002;110 Suppl 5:883-6.
18. Metzler M, Degen GH. Sex hormones and neoplasia: Liver tumors in rodents. Arch Toxicol Suppl 1987;10:251-63.
19. Watanabe S, Kobayashi Y. Exogenous hormones and cancer. Jpn J Clin Oncol 1993;23:1-13.
20. Couse JF, Davis VL, Hanson RB, Jefferson WN, McLachlan JA, Bullock BC, et al. Accelerated onset of uterine tumors in transgenic mice with aberrant expression of the estrogen receptor after neonatal exposure to diethylstilbestrol. Mol Carcinog 1997;19:236-42.
21. Persson I. Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 2000;74:357-64.
22. Waalkes MP, Keefer LK, Diwan BA. Induction of proliferative lesions of the uterus, testes, and liver in Swiss mice given repeated injections of sodium arsenate: Possible estrogenic mode of action. Toxicol Appl Pharmacol 2000;166:24-35.
23. Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, et al. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 2002;277:24353-60.
24. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996;36:203-32.
25. Deane NG, Parker MA, Aramandla R, Diehl L, Lee WJ, Washington MK, et al. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res 2001;61:5389-95.
26. Terry MB, Gammon MD, Schoenberg JB, Brinton LA, Arber N, Hibshoosh H. Oral contraceptive use and cyclin D1 overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 2002;11:1100-3.
27. Lu T, Liu J, LeCluyse EL, Zhou YS, Cheng ML, Waalkes MP. Application of cDNA microarray to the study of arsenic-induced liver diseases in the population of Guizhou, China. Toxicol Sci 2001;59:185-92.
28. Liu W, Saint DA. A new quantitative method of real time reverse transcription polymerase chain reaction assay based on simulation of polymerase chain reaction kinetics. Anal Biochem 2002;302:52-9.
29. Balaghi M, Wagner C. DNA methylation in folate deficiency: use of CpG methylase. Biochem Biophys Res Commun 1993;193:1184-90.
30. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994;22:2990-97.
31. Kos M, O'Brien S, Flouriot G, Gannon F. Tissue-specific expression of multiple mRNA variants of the mouse estrogen receptor alpha gene. FEBS Lett 2000;477:15-20.
32. Sueyoshi T, Yokomori N, Korach KS, Negishi M. Developmental action of estrogen receptor alpha feminizes the growth hormone-Stat5b pathway and expression of Cyp2a4 and Cyp 2d9 genes in mouse liver. Mol Pharmacol 1999;56:473-7.
33. Jarukamjorn K, Sakuma T, Nemoto N. Discriminating activation of CYP2B9 expression in male C57BL/6 mouse liver by beta-estradiol. Biochem Biophys Res Commun 2000;279:288-92.
34. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci U S A 1997;94:10907-12.
35. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 2001;61:7025-9.
36. Sasaki M, Tanaka Y, Perinchery G, Dharia A, Kotcherguina I, Fujimoto S, et al. Methylation and inactivation of the estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst 2002;94:384-90.
37. Hart LL, Davie JR. The estrogen receptor: More than the average transcription factor. Biochem Cell Biol 2002;80:335-41.
38. Archey WB, McEachern KA, Robson M, Offit K, Vaziri SA, Casey G, et al. Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers. Oncogene 2002;21:7034-41.
39. Okoji RS, Yu RC, Maronpot RR, Froines JR. Sodium arsenite administration via drinking water increases genome-wide and Ha-ras DNA hypomethylation in methyl-deficient C57BL/6J mice. Carcinogenesis 2002;23: 777-85.
40. Sonnenschein C, Soto AM. An updated review of environmental estrogen and androgen mimics and antagonists. J Steroid Biochem Mol Biol 1998; 65:143-50.
41. Barrett JC, Wong A, McLachlan JA. Diethylstilbestrol induces neoplastic transformation without measurable gene mutation at two loci. Science 1981;212:1402-4.
42. Li JJ, Li SA. Estrogen carcinogenesis in hamster tissues: A critical review. Endocr Rev 1990;11:524-31.
43. Newbold RR, Bullock BC, McLachlan JA. Uterine adenocarcinoma in mice following developmental treatment with estrogens: A model for hormonal carcinogenesis. Cancer Res 1990;50:7677-81.
44. Mizumoto H, Saito T, Ashihara K, Nishimura M, Tanaka R, Kudo R. Acceleration of invasive activity via matrix metalloproteinases by transfection of the estrogen receptor-alpha gene in endometrial carcinoma cells. Int J Cancer 2002;100:401-6.
45. Sherr CJ. G1 phase progression: Cycling on cue. Cell 1994;79:551-5.
46. Uto H, Ido A, Moriuchi A, Onaga Y, Nagata K, Onaga M, et al. Transduction of antisense cyclin D1 using two-step gene transfer inhibits the growth of rat hepatoma cells. Cancer Res 2001;61:4779-83.
47. Trouba KJ, Wauson EM, Vorce RL. Sodium arsenite-induced dysregulation of proteins involved in proliferative signaling. Toxicol Appl Pharmacol 2000;164:161-70.
48. Chen H, Liu J, Zhao CQ, Diwan BA, Merrick BA, Waalkes MP. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation. Toxicol Appl Pharmacol 2001;175:260-8.
49. Vogt BL, Rossman TG. Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts-a possible mechanism for arsenite's comutagenicity. Mutat Res 2001;478:159-68.
50. Rossman TG, Uddin AN, Burns FJ, Bosland MC. Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: An animal model for arsenic carcinogenesis. Toxicol Appl Pharmacol 2001;176:64-71.
51. Wei M, Wanibuchi H, Morimura K, Iwai S, Yoshida K, Endo G, et al. Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis 2002;23: 1387-97.
52. Basu A, Mahata J, Gupta S, Giri AK. Genetic toxicology of a paradoxical human carcinogen, arsenic: A review. Mutat Res 2001;488:171-94.
53. Prall OW, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 1997;272:10882-94.
54. Planas-Silva MD, Weinberg RA. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 1997;17:4059-69.
55. Musgrove EA, Sutherland RL. Cell cycle control by steroid hormones. Semin Cancer Biol 1994;5:381-9.
56. Hui R, Cornish AL, McClelland RA, Robertson JF, Blamey RW, Musgrove EA, et al. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res 1996;2: 923-8.
57. Li-Hawkins J, Lund EG, Bronson AD, Russell DW. Expression cloning of an oxysterol 7alpha-hydroxylase selective for 24-hydroxycholesterol. J Biol Chem 2000;275:16543-9.
58. Gemzik B, Jacob S, Jennings S, Veltman J, Parkinson A. Species differences in 5 alpha-androstane-3 beta,17 beta-diol hydroxylation by rat, monkey, and human prostate microsomes. Arch Biochem Biophys 1992;296: 374-83.
59. McLachlan JA, Burow M, Chiang TC, Li SF. Gene imprinting in developmental toxicology: A possible interface between physiology and pathology. Toxicol Lett 2001;120:161-4.
60. Recillas-Targa F. DNA methylation, chromatin boundaries, and mechanisms of genomic imprinting. Arch Med Res 2002;33:428-38.
61. Hong F, Zhang A, Huang X, Liu Z. [The expression of P16, P21(WAF1/ CIP1) and cyclin D1 proteins in skin of patients with arseniasis caused by coal-burning and their significance] Zhonghua Yu Fang Yi Xue Za Zhi 2000;34:324-6.